

CELLDEX THERAPEUTICS, INC.

Reported by CAVANAUGH SARAH

FORM 3

(Initial Statement of Beneficial Ownership)

Filed 06/16/17 for the Period Ending 06/15/17

Address 53 FRONTAGE ROAD

SUITE 220

HAMPTON, NJ 08827

Telephone 908-200-7500

CIK 0000744218

Symbol CLDX

SIC Code 2835 - In Vitro and In Vivo Diagnostic Substances

Industry Biotechnology & Medical Research

Sector Healthcare

Fiscal Year 12/31



UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response... 0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person Cavanaugh Sarah		Statement (MM/DD/YYYY)		3. Issuer Name and Ticker or Trading Symbol Celldex Therapeutics, Inc. [CLDX]				
(Last) (First) (Middle)	4. Rela	tionship of Re	eporting Perso	n(s) to Issuer	Check all application	able)		
C/O CELLDEX THERAPEUTIONC., 53 FRONTAGE ROAD, SUITE 220	X_	Director X Officer (give title below) SVP of Corp. Affairs & Admin		10% Owner Other (specify below)				
(Street) HAMPTON, NJ 08827 (City) (State) (Zip)		5. If Amendment, Date Original Filed (MM/DD/YYYY)		6. Individual or Joint/Group Filing (Check Applicable Line) _X_Form filed by One Reporting Person Form filed by More than One Reporting Person				
	Tab	ole I - Non-De	erivative Secu	rities Benefic	ially Owned			
1.Title of Security (Instr. 4)		2. Amount of Securit Beneficially Owned (Instr. 4)			*	4. Nature of Indirect Beneficial Ownership (Instr. 5)		
Common Stock, par value \$0.001	per share	r share 476			D			
Table II - Derivativ	ve Securities	Beneficially (Owned (<i>e.g.</i> ,	, puts, calls, w	varrants, options	s, convertible secu	ırities)	
1. Title of Derivate Security (Instr. 4)	2. Date Exer Expiration I (MM/DD/YYY	Date			4. Conversio or Exercise Price of Derivative	Form of Derivative Security:	6. Nature of Indirect Beneficial Ownership (Instr. 5)	
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Security	Direct (D) or Indirect (I) (Instr. 5)		
Employee Stock Option (right to buy)	<u>(1)</u>	8/15/2022	Common Stock	7500	\$4.71	D		
Employee Stock Option (right to buy)	(2)	7/1/2023	Common Stock	20000	\$16.36	D		
Employee Stock Option (right to buy)	(3)	6/4/2024	Common Stock	25000	\$13.45	D		
Employee Stock Option (right to buy)	<u>(4)</u>	6/10/2025	Common Stock	30000	\$25.41	D		
Employee Stock Option (right to buy)	<u>(5)</u>	6/8/2026	Common Stock	22000	\$4.72	D		

Explanation of Responses:

- (1) The option became exercisable as to 25% of the shares on 8/15/2013 and the remaining shares vested quarterly (in equal amounts) over the subsequent 12 quarters. This option is currently fully vested.
- (2) The option became exercisable as to 25% of the shares on 7/1/2014 and the remaining shares vested quarterly (in equal amounts) over the subsequent 12 quarters.
- (3) The option became exercisable as to 25% of the shares on 6/4/2015 and the remaining shares vested quarterly (in equal amounts) over the subsequent 12 quarters.
- (4) The option became exercisable as to 25% of the shares on 6/10/2016 and the remaining shares vested quarterly (in equal amounts) over the subsequent 12

quarters.

(5) The option became exercisable as to 25% of the shares on 6/8/2017 and the remaining shares vest quarterly (in equal amounts) over the subsequent 12 quarters.

Reporting Owners

Reporting Owner Name / Address	Relationships				
Reporting Owner Name / Address	Director	10% Owner	Officer	Other	
Cavanaugh Sarah C/O CELLDEX THERAPEUTICS, INC. 53 FRONTAGE ROAD, SUITE 220 HAMPTON, NJ 08827			SVP of Corp. Affairs & Admin.		

Signatures

/s/ Sam Martin, attorney-in-fact for Sarah Cavanaugh	6/16/2017
** Signature of Reporting Person	Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

POWER OF ATTORNEY

Know all by those present, that the undersigned hereby constitutes and appoints each of Sam Martin and Anthony S. Marucci his true and lawful attorney-in-fact to:

- 1. execute for and on behalf of the undersigned Schedules 13D and 13G, Form ID, and Forms 3, 4 and 5 in accordance with Sections 13 and 16(a) of the Securities Exchange Act of 1934 and the rules thereunder;
- 2. do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Schedules 13D or 13G, Form ID and Forms 3, 4 or 5, and the timely filing of such Forms with the United States Securities and Exchange Commission and any other authority; and
- 3. take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, including without limitation the execution and filing of a Form 4 with respect to a transaction which may be reported on a Form 5, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in his discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform all and every act and thing whatsoever requisite, necessary and proper to be done in the exercise of any of the rights and powers herein granted, as fully and to all intents and purposes as he might or could do in person, with full power of substitution and resubstitution, hereby ratifying and confirming all that such attorney-in-fact, or his substitute or substitutes, shall lawfully do or cause to be done by virtue of this Power of Attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming any of the undersigned's responsibilities to comply with Sections 13 and 16 of the Securities Exchange Act of 1934.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 12th day of June, 2017.

/s/Sarah Cavanaugh Name: Sarah Cavanaugh